Menu
Recruiting NCT05516277

Insomnia Treatment and Cardiometabolic Health in Older Adults With Posttraumatic Stress Disorder

No phase Interventional Posttraumatic Stress Disorder Insomnia Cardiovascular Diseases Metabolic Disease

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Behavioral Sleep Education Intervention.
Who it may be relevant to
Registry conditions: Posttraumatic Stress Disorder, Insomnia, Cardiovascular Diseases, Metabolic Disease. Basic parameters: from 50 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Overview

This pilot pre-post trial will address a gap in knowledge related to addressing modifiable risk factors for cardiometabolic disease through treating residual insomnia, sleep difficulties that remain after successful treatment of another condition, in the context of PTSD in understudied older adults. This study provides a non-medication treatment for PTSD called Cognitive Processing Therapy (CPT) followed by a non-medication sleep education and treatment program (Cognitive Behavioral Therapy for Insomnia, CBT-I) for sleep problems that remain after completing PTSD treatment in older adults with PTSD. The aims of this project are to evaluate 1) the added benefits of treating residual insomnia on sleep and PTSD symptoms; 2) the added benefits of treating residual insomnia following CPT on cardiometabolic risk biomarkers and quality of life; and 3) the durability of the sleep, PTSD, cardiometabolic and quality of life benefits of treating residual insomnia following CPT at 6-month follow-up in older adults with PTSD.

Detailed description

Both insomnia and Post Traumatic Stress Disorder (PTSD) are independent risk factors for cardiometabolic diseases; the leading causes of morbidity and mortality in the US for which the growing geriatric population is at elevated risk. PTSD and insomnia disorder frequently co-occur yet require unique treatments, as sleep difficulties are one of the most common residual symptoms that remain after completing an evidence-based PTSD treatment.

This pilot pre-post trial provides a non-medication treatment for PTSD called Cognitive Processing Therapy (CPT) followed by a non-medication sleep education and treatment program (Cognitive Behavioral Therapy for Insomnia, CBT-I) for sleep problems that remain after completing PTSD treatment in older adults with PTSD. Individuals over 50 years of age, who have received care at the VA Greater Los Angeles Healthcare System, and who have been exposed to a stressful or traumatic life event will be recruited for this study.

Participants will be asked to complete a baseline evaluation that involves (a) being asked questions about health, medications, personal information, quality of life, sleep patterns and habits, mood, and stressful/traumatic experiences; (b) wearing a blood pressure monitor at home for 24 hours; (c) wearing a continuous glucose monitor sensor that contains a small filament (a thread-sized needle) inserted into the upper arm or abdomen for 7 consecutive days; (d) wearing a wristwatch device that measures sleep/wake patterns for 7 consecutive days; and (e) completing a daily sleep diary for 7 consecutive days. Participants may also be screened for sleep apnea with a portable sleep apnea monitoring device with sensors worn on the wrist, index finger and chest for one night.

Information from the baseline evaluation and medical records will be reviewed by the research team to determine whether an individual is eligible and likely able to complete all future study activities. Participants will be contacted to be advised of their study eligibility status. If eligible after the baseline assessment, study staff will review future study activities and confirm the participant's interest in continuing in the study. All eligible and interested participants will then receive an evidence-based PTSD treatment (CPT; 12 sessions). Following completion of the PTSD treatment, participants will receive a sleep education program (CBT-I; 5 sessions). For eligible individuals, participation in this research will last about 11 months.

Main study outcomes assessments from the baseline evaluation will be repeated three times: (1) one week after completion of the PTSD treatment; (2) one week after completion of the sleep education program; and (3) 6-months after the sleep education program ends. Data will be analyzed using "intention to treat" principles, using appropriate statistical methods for pilot clinical trials.

The investigators hope to determine how these treatment programs affect health in older adults with PTSD and insomnia. Findings from this pilot study will expand our understanding of the relationships between evidence-based insomnia and trauma treatments and key outcomes of sleep, PTSD symptoms, cardiometabolic health and quality of life in older adults with PTSD and insomnia while informing future research.

Interventions

  • Behavioral Behavioral Sleep Education Intervention
    Manual-based education program focusing on behavioral sleep techniques provided in individual 60-minute sessions for 5 weekly sessions.

Primary outcome measures

  • Consensus sleep diary questionnaire [Time frame: Change from baseline to 1 week after completion of sleep intervention]
  • PTSD Checklist for DSM-5 (PCL-5) [Time frame: Change from baseline to 1 week after completion of sleep intervention]
  • 24-hr ambulatory blood pressure monitoring (ABPM) blood pressure variability [Time frame: Change from baseline to 1 week after completion of sleep intervention]
  • 24-hr ambulatory blood pressure monitoring (ABPM) systolic/diastolic loads [Time frame: Change from baseline to 1 week after completion of sleep intervention]
  • 24-hr ambulatory blood pressure monitoring (ABPM) change in blood pressure day to night [Time frame: Change from baseline to 1 week after completion of sleep intervention]
  • WHOQOL-BREF questionnaire [Time frame: Change from baseline to 1 week after completion of sleep intervention]
Secondary outcome measures (6)
  • Homeostatic Model Assessment of Insulin Resistance (HOMA) [Time frame: Change from baseline to 1 week after completion of sleep intervention]
  • Hemoglobin A1c (HbA1c) [Time frame: Change from baseline to 6 months after completion of sleep intervention]
  • Body Mass Index (BMI) [Time frame: Change from baseline to 1 week after completion of sleep intervention]
  • Central adiposity [Time frame: Change from baseline to 1 week after completion of sleep intervention]
  • Actigraphy [Time frame: Change from baseline to 1 week after completion of sleep intervention]
  • Dyslipidemia [Time frame: Change from baseline to 1 week after completion of sleep intervention]

Eligibility criteria

Inclusion criteria

  • Community-dwelling Veterans aged 50 years and older
  • Received care from a Veterans Health Administration (VHA) facility in the prior year
  • Diagnosis of PTSD
  • Diagnosis of insomnia disorder
  • Lives within a 50-mile radius of the research offices at the VA Sepulveda Ambulatory Care Center

Exclusion criteria

  • Active substance use or in recovery with less than 90 days of sobriety
  • Too ill to engage in the study procedures (e.g., unable to attend the in-person meetings)
  • Unable to self-consent to participate
  • Unstable housing (as this will impact the research team's ability to retrieve costly and difficult to replace monitoring equipment)
  • Severe cardiovascular or respiratory disease (e.g., ventilatory failure, CHF)
  • Unstable medical or psychiatric disorders (which are a contraindication for behavioral treatment of insomnia)
  • Comorbid sleep disorders (i.e., central sleep apnea syndrome, diagnosed narcolepsy or circadian rhythm sleep-wake phase disorders) based on medical record review and baseline assessment data, or untreated, severe sleep disordered breathing (SDB) as assessed via WatchPAT or previous clinical evaluation (apnea-hypopnea index \[AHI\] ≥ 30; or AHI ≥ 15 plus Epworth Sleepiness Scale \[ESS\] score ≥ 10) that better explain sleep difficulties

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Treatment

Study locations

United States · 1 center
  • VA Greater Los Angeles Healthcare System — North Hills

Identifiers

NCT: NCT05516277 · 1K23HL157754-01A1

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗